Ichwaku Rastogi

Anti-tumor DNA vaccines are relatively new therapeutic approach in cancer treatment. They elicit humoral as well as cellular immune response against the encoded tumor antigen. McNeel lab has shown that B cells but not monocytes or DC's are the antigen presenting cells which expand CD8+ T-cells, eliciting an anti-tumor immune response. My role is to develop a way for specifically delivering the vaccine to B-cells and then to test if that would be a better treatment modality.